HRP20100654T1 - Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata - Google Patents
Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata Download PDFInfo
- Publication number
- HRP20100654T1 HRP20100654T1 HR20100654T HRP20100654T HRP20100654T1 HR P20100654 T1 HRP20100654 T1 HR P20100654T1 HR 20100654 T HR20100654 T HR 20100654T HR P20100654 T HRP20100654 T HR P20100654T HR P20100654 T1 HRP20100654 T1 HR P20100654T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- pain
- disorder
- disease
- migraine
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 49
- 208000035475 disorder Diseases 0.000 claims 44
- 208000002193 Pain Diseases 0.000 claims 20
- 208000019695 Migraine disease Diseases 0.000 claims 14
- 206010027599 migraine Diseases 0.000 claims 14
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 208000019901 Anxiety disease Diseases 0.000 claims 10
- 230000036506 anxiety Effects 0.000 claims 10
- 206010015037 epilepsy Diseases 0.000 claims 10
- 201000000980 schizophrenia Diseases 0.000 claims 10
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 8
- 206010012335 Dependence Diseases 0.000 claims 6
- 208000030507 AIDS Diseases 0.000 claims 5
- 206010002383 Angina Pectoris Diseases 0.000 claims 5
- 206010002660 Anoxia Diseases 0.000 claims 5
- 241000976983 Anoxia Species 0.000 claims 5
- 206010003805 Autism Diseases 0.000 claims 5
- 208000020706 Autistic disease Diseases 0.000 claims 5
- 206010004663 Biliary colic Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 208000000094 Chronic Pain Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 5
- 201000010374 Down Syndrome Diseases 0.000 claims 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 5
- 208000010412 Glaucoma Diseases 0.000 claims 5
- 201000005569 Gout Diseases 0.000 claims 5
- 206010019196 Head injury Diseases 0.000 claims 5
- 208000023105 Huntington disease Diseases 0.000 claims 5
- 208000013016 Hypoglycemia Diseases 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 5
- 206010065390 Inflammatory pain Diseases 0.000 claims 5
- 208000008930 Low Back Pain Diseases 0.000 claims 5
- 208000036626 Mental retardation Diseases 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 5
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 5
- 208000004550 Postoperative Pain Diseases 0.000 claims 5
- 206010038419 Renal colic Diseases 0.000 claims 5
- 206010039966 Senile dementia Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 5
- 206010044688 Trisomy 21 Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 208000005298 acute pain Diseases 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 230000007953 anoxia Effects 0.000 claims 5
- 206010003246 arthritis Diseases 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 5
- 235000019788 craving Nutrition 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims 5
- 208000037906 ischaemic injury Diseases 0.000 claims 5
- 230000005906 menstruation Effects 0.000 claims 5
- 208000004296 neuralgia Diseases 0.000 claims 5
- 230000002981 neuropathic effect Effects 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 201000001119 neuropathy Diseases 0.000 claims 5
- 230000007823 neuropathy Effects 0.000 claims 5
- 208000020016 psychiatric disease Diseases 0.000 claims 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 5
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj ili njegova farmaceutski prihvatljiva sol, naznaceni time da su odabrani iz skupine koja se sastoji od spojeva prikazanih u slijedecoj tablici:
Claims (17)
1. Spoj ili njegova farmaceutski prihvatljiva sol, naznačeni time da su odabrani iz skupine koja se sastoji od spojeva prikazanih u slijedećoj tablici:
[image]
[image]
[image]
[image]
2. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, naznačeni time da je spoj:
[image]
3. Farmaceutska formulacija, naznačena time da kao aktivni sastojak sadrži terapeutski djelotvornu količinu spoja ili njegove farmaceutski prihvatljive soli prema patentnom zahtjevu 1 zajedno sa jednim ili više farmaceutski prihvatljivih otapala, ekscipijenata i/ili inertnih nosača.
4. Farmaceutska formulacija prema patentnom zahtjevu 3, naznačena time da je namijenjena za upotrebu kod prevencije i/ili liječenja poremećaja posredovanog sa mGluR5 receptorom, pri čemu je poremećaj odabran iz skupine koja se sastoji od neuroloških poremećaja, psihijatrijskih poremećaja, kroničnih poremećaja bola, akutnih poremećaja bola, gastrointestinalnih poremećaja, Alzheimerove bolesti, senilne demencije, AIDS-om inducirane demencije, Parkinsonsonove bolesti, amiotrofične lateralne skleroze, Huntingtonove koreje, migrene, epilepsije, shizofrenije, depresije, anksioznosti, akutne anksioznosti, obsesivno kompulzivnog poremećaja, oftamoloških poremećaja, dijabetskih retinopatija, glaukoma, auditornih neuropatskih poremećaja, kemoterapijom induciranih neuropatija, post-herpetičkih neuralgija i trigeminalne neuralgije, tolerancije, zavisnosti, ovisnosti i poremećaja žudnje, neurorazvojnih poremećaja, autizma, mentalne zaostalosti, shizofrenije, Downovog sindroma, bola povezanog sa migrenom, upalnih boli, neuropatskih poremećaja boli, artritisa i reumatoidnih bolesti, boli u donjem dijelu leđa, postoperativne boli; boli povezane sa anginom, bubrežnim ili žučnim kolikama, menstruacijom, migrenom, gihtom; moždanog udara, ozljeda glave, anoksije i ishemijskih ozljeda, hipoglikemije, kardiovaskularnih bolesti, gastroezofagealne refluksne bolesti (GERD) i epilepsije.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1 ili 2, naznačeni time da su za upotrebu u terapiji.
6. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1 ili 2, naznačeni time da su za upotrebu kod prevencije i/ili liječenja poremećaja posredovanog sa mGluR5 receptorom, pri čemu je poremećaj odabran iz skupine koja se sastoji od neuroloških poremećaja, psihijatrijskih poremećaja, kroničnih poremećaja bola, akutnih poremećaja bola, gastrointestinalnih poremećaja, Alzheimerove bolesti, senilne demencije, AIDS-om inducirane demencije, Parkinsonsonove bolesti, amiotrofične lateralne skleroze, Huntingtonove koreje, migrene, epilepsije, shizofrenije, depresije, anksioznosti, akutne anksioznosti, obsesivno kompulzivnog poremećaja, oftamoloških poremećaja, dijabetskih retinopatija, glaukoma, auditornih neuropatskih poremećaja, kemoterapijom induciranih neuropatija, post-herpetičkih neuralgija i trigeminalne neuralgije, tolerancije, zavisnosti, ovisnosti i poremećaja žudnje, neurorazvojnih poremećaja, autizma, mentalne zaostalosti, shizofrenije, Downovog sindroma, bola povezanog sa migrenom, upalnih boli, neuropatskih poremećaja boli, artritisa i reumatoidnih bolesti, boli u donjem dijelu leđa, postoperativne boli; boli povezane sa anginom, bubrežnim ili žučnim kolikama, menstruacijom, migrenom, gihtom; moždanog udara, ozljeda glave, anoksije i ishemijskih ozljeda, hipoglikemije, kardiovaskularnih bolesti, gastroezofagealne refluksne bolesti (GERD) i epilepsije.
7. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 6, naznačeni time da je poremećaj neurološki poremećaj.
8. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 6, naznačeni time da je poremećaj psihijatrijski poremećaj.
9. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 6, naznačeni time da je poremećaj odabran između kroničnih i akutnih poremećaja boli.
10. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 6, naznačeni time da je poremećaj gastrointestinalni poremećaj.
11. Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 6, naznačeni time da je poremećaj odabran iz skupine koja se sastoji od Alzheimerove bolesti, senilne demencije, AIDS-om inducirane demencije, Parkinsonsonove bolesti, amiotrofne lateralne skleroze, Huntingtonove koreje, migrene, epilepsije, shizofrenije, depresije, anksioznosti, akutne anksioznosti, opsesivno kompulzivnog poremećaja, oftamoloških poremećaja, dijabetičkih retinopatija, glaukoma, auditornih neuropatičkih poremećaja, kemoterapijom induciranih neuropatija, post-herpetičkih neuralgija i trigeminalne neuralgije, tolerancije, zavisnosti, ovisnosti i poremećaja žudnje, neurorazvojnih poremećaja, autizma, mentalne zaostalosti, shizofrenije, Downovog sindroma, bola povezanog sa migrenom, upalne boli, neuropatskih poremećaja boli, artritisa i reumatoidnih bolesti, boli u donjem delu leđa, postoperativne boli; boli povezane sa anginom, bubrežnim ili žučnim kolikama, menstruacijom, migrenom, gihtom; moždanog udara, ozljeda glave, anoksije i ishemijskih ozljeda, hipoglikemije, kardiovaskularnih bolesti, gastroezofagealne refluksne bolesti (GERD) i epilepsije.
12. Upotreba spoja ili njegove farmaceutski prhvatljive soli prema patentnom zahtjevu 1 ili 2, naznačena time da je za proizvodnju lijeka za upotrebu kod prevencije i/ili liječenja poremećaja posredovanog mGluR55 receptorom, pri čemu je poremećaj odabran iz skupine koja se sastoji od neuroloških poremećaja, psihijatrijskih poremećaja, kroničnih poremećaja bola, akutnih poremećaja bola, gastrointestinalnih poremećaja, Alzheimerove bolesti, senilne demencije, AIDS-om inducirane demencije, Parkinsonsonove bolesti, amiotrofične lateralne skleroze, Huntingtonove koreje, migrene, epilepsije, shizofrenije, depresije, anksioznosti, akutne anksioznosti, obsesivno kompulzivnog poremećaja, oftamoloških poremećaja, dijabetskih retinopatija, glaukoma, auditornih neuropatskih poremećaja, kemoterapijom induciranih neuropatija, post-herpetičkih neuralgija i trigeminalne neuralgije, tolerancije, zavisnosti, ovisnosti i poremećaja žudnje, neurorazvojnih poremećaja, autizma, mentalne zaostalosti, shizofrenije, Downovog sindroma, bola povezanog sa migrenom, upalnih boli, neuropatskih poremećaja boli, artritisa i reumatoidnih bolesti, boli u donjem dijelu leđa, postoperativne boli; boli povezane sa anginom, bubrežnim ili žučnim kolikama, menstruacijom, migrenom, gihtom; moždanog udara, ozljeda glave, anoksije i ishemijskih ozljeda, hipoglikemije, kardiovaskularnih bolesti, gastroezofagealne refluksne bolesti (GERD) i epilepsije.
13. Upotreba prema patentnom zahtjevu 12, naznačena time da je poremećaj neurološki poremećaj.
14. Upotreba prema patentnom zahtjevu 12, naznačena time da je poremećaj psihijatrijski poremećaj.
15. Upotreba prema patentnom zahtjevu 12, naznačena time da je poremećaj odabran između hroničnih i akutnih poremećaja boli.
16. Upotreba prema patentnom zahtjevu 12, naznačena time da je poremećaj gastrointestinalni poremećaj.
17. Upotreba prema patentnom zahtjevu 12, naznačena time da je poremećaj odabran iz skupine koja se sastoji od Alzheimerove bolesti, senilne demencije, AIDS-om inducirane demencije, Parkinsonsonove bolesti, amiotrofične lateralne skleroze, Huntingtonove koreje, migrene, epilepsije, shizofrenije, depresije, anksioznosti, akutne anksioznosti, obsesivno kompulzivnog poremećaja, oftamoloških poremećaja, dijabetskih retinopatija, glaukoma, auditornih neuropatskih poremećaja, kemoterapijom induciranih neuropatija, post-herpetičkih neuralgija i trigeminalne neuralgije, tolerancije, zavisnosti, ovisnosti i poremećaja žudnje, neurorazvojnih poremećaja, autizma, mentalne zaostalosti, shizofrenije, Downovog sindroma, bola povezanog sa migrenom, upalnih boli, neuropatskih poremećaja boli, artritisa i reumatoidnih bolesti, boli u donjem dijelu leđa, postoperativne boli; boli povezane sa anginom, bubrežnim ili žučnim kolikama, menstruacijom, migrenom, gihtom; moždanog udara, ozljeda glave, anoksije i ishemijskih ozljeda, hipoglikemije, kardiovaskularnih bolesti i epilepsije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60896004P | 2004-02-18 | 2004-02-18 | |
| PCT/US2005/004774 WO2006014185A1 (en) | 2004-02-18 | 2005-02-15 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100654T1 true HRP20100654T1 (hr) | 2011-01-31 |
Family
ID=35447957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100654T HRP20100654T1 (hr) | 2004-02-18 | 2010-11-29 | Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US7585881B2 (hr) |
| EP (2) | EP2311830A1 (hr) |
| JP (1) | JP4912157B2 (hr) |
| CN (2) | CN101096368A (hr) |
| AT (1) | ATE483706T1 (hr) |
| AU (1) | AU2005270208A1 (hr) |
| BR (1) | BRPI0507497A (hr) |
| CA (1) | CA2555566A1 (hr) |
| CY (1) | CY1110965T1 (hr) |
| DE (1) | DE602005023963D1 (hr) |
| DK (1) | DK1723144T3 (hr) |
| ES (1) | ES2352110T3 (hr) |
| HK (1) | HK1099285A1 (hr) |
| HR (1) | HRP20100654T1 (hr) |
| IL (1) | IL177394A0 (hr) |
| NO (1) | NO20063599L (hr) |
| NZ (1) | NZ548954A (hr) |
| PL (1) | PL1723144T3 (hr) |
| PT (1) | PT1723144E (hr) |
| RS (1) | RS51516B (hr) |
| RU (1) | RU2370495C2 (hr) |
| SG (1) | SG146657A1 (hr) |
| SI (1) | SI1723144T1 (hr) |
| UA (1) | UA84318C2 (hr) |
| UY (1) | UY28766A1 (hr) |
| WO (1) | WO2006014185A1 (hr) |
| ZA (1) | ZA200606551B (hr) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2352568C9 (ru) * | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1740559B1 (en) * | 2004-04-20 | 2014-10-15 | Merck Sharp & Dohme Corp. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2006080533A1 (ja) * | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | ３－アミノ－１,２,４－トリアゾール誘導体 |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
| TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| EP2081905B1 (en) * | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| AU2008257559B2 (en) | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
| WO2009010455A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as modulators of metabotropic glutamate receptors |
| WO2009051556A1 (en) | 2007-10-19 | 2009-04-23 | Astrazeneca Ab | Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) |
| WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
| WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
| WO2009061652A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| CA2718166A1 (en) * | 2008-03-03 | 2009-09-17 | Stiefel Laboratories, Inc. | Processes for preparing enantiomerically pure diol and dioxolane compounds |
| EP3782991A1 (en) | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| JP5749162B2 (ja) * | 2008-07-10 | 2015-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するスルホン化合物 |
| CA2733922A1 (en) * | 2008-08-12 | 2010-02-18 | Astrazeneca Ab | A crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| EP2323658A4 (en) * | 2008-08-12 | 2011-10-05 | Astrazeneca Ab | NEW CRYSTALLINE FORM OF (5- {(IR) -1- [5- (3-CHLOROPHENYL) ISOXAZOL-3-YL] ETHOXY} -4-METHYL-4H-L, 2, 4-TRIAZOL-3-YL) - PYRIDINE |
| KR20110063485A (ko) * | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물 |
| US20110306768A1 (en) * | 2008-12-18 | 2011-12-15 | Astrazeneca Ab | Processes for the manufacture of 3--pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)-l,2,4-triazole, and (1r)-1-[2-(3-methylphenyl)-2h-tetrazol-5-yl]ethanol |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調する複素環化合物 |
| CA2756989A1 (en) * | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
| EP2438052A1 (en) * | 2009-06-05 | 2012-04-11 | Oslo University Hospital HF | Azole derivatives as wtn pathway inhibitors |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| US8383651B2 (en) * | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| LT3406142T (lt) * | 2009-11-13 | 2021-06-10 | Receptos Llc | Selektyvūs sfingozino 1 fosfato receptoriaus moduliatoriai ir chiralinės sintezės būdai |
| MX2012005559A (es) * | 2009-11-13 | 2012-08-23 | Receptos Inc | Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato. |
| AU2010320041B2 (en) | 2009-11-13 | 2015-04-02 | Receptos Llc | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| WO2011082010A1 (en) | 2009-12-29 | 2011-07-07 | Eli Lilly And Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
| CN101712641B (zh) * | 2009-12-29 | 2013-05-08 | 江苏工业学院 | 一种甲硫基苯甲酸的制备方法 |
| US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
| EP2632900A2 (en) * | 2010-10-28 | 2013-09-04 | Merck Sharp & Dohme Corp. | Caprolactam mglur5 receptor modulators |
| RU2013128448A (ru) | 2010-12-08 | 2015-01-20 | Осло Юниверсити Хоспитал Хф | Производные триазола в качестве ингибиторов сигнального пути wnt |
| DE102010063974B4 (de) * | 2010-12-22 | 2021-10-07 | Thomas Rühl | Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung |
| KR20140018286A (ko) | 2011-03-18 | 2014-02-12 | 노파르티스 아게 | 파킨슨병에서의 도파민 유발 이상운동증에서 사용하기 위한 알파 7 니코틴성 아세틸콜린 수용체 활성화제 및 mGluR5 길항제의 조합물 |
| US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
| JP6858129B2 (ja) * | 2015-03-05 | 2021-04-14 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 置換されたフェニルイソオキサゾリン誘導体の製造方法 |
| MX2017011612A (es) * | 2015-03-10 | 2018-03-23 | Aurigene Discovery Tech Ltd | Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores. |
| HRP20220258T1 (hr) | 2015-03-10 | 2022-04-29 | Aurigene Discovery Technologies Limited | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| SG11201810600WA (en) | 2016-06-13 | 2018-12-28 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| WO2019073399A1 (en) | 2017-10-11 | 2019-04-18 | Aurigene Discovery Technologies Limited | CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3 |
| US11497734B2 (en) | 2017-11-03 | 2022-11-15 | Aurigene Discovery Technologies Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
| JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
| CN111448181B (zh) * | 2017-11-16 | 2023-05-19 | 蒙特多力士有限公司 | 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法 |
| DK3860989T3 (da) | 2018-10-05 | 2023-05-01 | Forma Therapeutics Inc | Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30) |
| CN113302190A (zh) | 2019-01-15 | 2021-08-24 | 吉利德科学公司 | Fxr(nr1h4)调节化合物 |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| EP3962481A4 (en) * | 2019-05-03 | 2023-03-22 | Praxis Precision Medicines, Inc. | KCNT1 INHIBITORS AND METHODS OF USE |
| AU2021206651B2 (en) * | 2020-01-07 | 2024-02-22 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| WO2022231872A1 (en) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4538833A (en) * | 1983-12-08 | 1985-09-03 | P I E International Inc. | Publication |
| US5403138A (en) * | 1991-10-09 | 1995-04-04 | Fuji Photo Film Co., Ltd. | Booklet album including a double-sided photograph and a method of making the same |
| US5332265A (en) * | 1993-01-22 | 1994-07-26 | Minnesota Mining And Manufacturing Company | Advertising assembly |
| UA75871C2 (en) | 1999-08-19 | 2006-06-15 | Nps Pharma Inc | 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors |
| US20040259917A1 (en) | 2001-12-19 | 2004-12-23 | Cosford Nicholas D.P. | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| TW200812986A (en) | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
| WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| RU2352568C9 (ru) * | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
-
2005
- 2005-02-09 US US11/053,752 patent/US7585881B2/en not_active Expired - Fee Related
- 2005-02-15 WO PCT/US2005/004774 patent/WO2006014185A1/en active Application Filing
- 2005-02-15 EP EP10182161A patent/EP2311830A1/en not_active Withdrawn
- 2005-02-15 PL PL05802855T patent/PL1723144T3/pl unknown
- 2005-02-15 CA CA002555566A patent/CA2555566A1/en not_active Abandoned
- 2005-02-15 NZ NZ548954A patent/NZ548954A/xx unknown
- 2005-02-15 US US10/588,702 patent/US20070179188A1/en not_active Abandoned
- 2005-02-15 BR BRPI0507497-5A patent/BRPI0507497A/pt not_active IP Right Cessation
- 2005-02-15 AU AU2005270208A patent/AU2005270208A1/en not_active Abandoned
- 2005-02-15 UA UAA200608867A patent/UA84318C2/ru unknown
- 2005-02-15 SG SG200806914-8A patent/SG146657A1/en unknown
- 2005-02-15 DE DE602005023963T patent/DE602005023963D1/de active Active
- 2005-02-15 SI SI200531175T patent/SI1723144T1/sl unknown
- 2005-02-15 RS RSP-2010/0525A patent/RS51516B/en unknown
- 2005-02-15 DK DK05802855.6T patent/DK1723144T3/da active
- 2005-02-15 CN CNA2007101278476A patent/CN101096368A/zh active Pending
- 2005-02-15 EP EP05802855A patent/EP1723144B1/en active Active
- 2005-02-15 ES ES05802855T patent/ES2352110T3/es active Active
- 2005-02-15 PT PT05802855T patent/PT1723144E/pt unknown
- 2005-02-15 CN CNA2005800043063A patent/CN1984907A/zh active Pending
- 2005-02-15 JP JP2006554165A patent/JP4912157B2/ja not_active Expired - Fee Related
- 2005-02-15 RU RU2006128446/04A patent/RU2370495C2/ru not_active IP Right Cessation
- 2005-02-15 AT AT05802855T patent/ATE483706T1/de active
- 2005-02-18 UY UY28766A patent/UY28766A1/es not_active Application Discontinuation
-
2006
- 2006-08-07 ZA ZA200606551A patent/ZA200606551B/en unknown
- 2006-08-08 NO NO20063599A patent/NO20063599L/no not_active Application Discontinuation
- 2006-08-09 IL IL177394A patent/IL177394A0/en unknown
-
2007
- 2007-05-22 HK HK07105399.9A patent/HK1099285A1/xx not_active IP Right Cessation
- 2007-08-18 US US11/840,953 patent/US20080045571A1/en not_active Abandoned
- 2007-08-18 US US11/840,954 patent/US20070293545A1/en not_active Abandoned
- 2007-08-18 US US11/840,955 patent/US20080015204A1/en not_active Abandoned
- 2007-08-18 US US11/840,952 patent/US20080015234A1/en not_active Abandoned
-
2010
- 2010-11-29 HR HR20100654T patent/HRP20100654T1/hr unknown
- 2010-12-03 CY CY20101101116T patent/CY1110965T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100654T1 (hr) | Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata | |
| JP2007523168A5 (hr) | ||
| RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
| JP2009510064A5 (hr) | ||
| HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
| HRP20120909T4 (hr) | Derivati oksadiazola i njihova uporaba kao pojaäśivaäśa-842 metabotropnih glutamatnih receptora | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20110570T1 (hr) | Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora | |
| JP2011500673A5 (hr) | ||
| RU2012140148A (ru) | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения | |
| WO2006017409A3 (en) | 1,3-disubstituted heteroaryl nmda/nr2b antagonists | |
| EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
| WO2006119504A3 (en) | Fused heterocyclic compounds, and compositions and uses thereof | |
| JP2020503323A5 (hr) | ||
| JP2009515934A5 (hr) | ||
| WO2010039186A3 (en) | Benzoxazoles useful as faah modulators and uses thereof | |
| PA8597301A1 (es) | Derivados de imidazol-4-il-etinil-piridina | |
| JP2015521642A5 (hr) | ||
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| MX2007007472A (es) | Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. | |
| IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| JP2018526345A5 (hr) | ||
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| JP2004524357A5 (hr) | ||
| HRP20201262T1 (hr) | Kombinacija inverzivnih agonista histamin-3 receptora sa inhibitorima acetilkolinesteraze |